Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The objective of this study is to demonstrate (1) the superior efficacy of VTE prophylaxis with oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days to SC enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days in men and women aged 40 years or above who have been hospitalized for a medical illness and (2) the non-inferiority of VTE prophylaxis with oral rivaroxaban 10 mg once daily administered for 10 +/- 4 days to SC enoxaparin 40 mg once daily for 10 +/- 4 days in the same patient population. The safety of rivaroxaban and enoxaparin will be compared as well.
Critère d'inclusion
- Prevention of venous thromboembolism in patients who have been hospitalized for a medical illness